Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22.053 patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Infectious meningitis and encephalitis in adults in Denmark: A prospective nationwide observational cohort study (DASGIB)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • J Eklöf
  • R Sørensen
  • T S Ingebrigtsen
  • P Sivapalan
  • I Achir
  • J B Boel
  • J Bangsborg
  • C Ostergaard
  • R B Dessau
  • U S Jensen
  • A Browatzki
  • T S Lapperre
  • J Janner
  • U M Weinreich
  • K Armbruster
  • T Wilcke
  • N Seersholm
  • J U S Jensen
Vis graf over relationer

OBJECTIVES: The role of Pseudomonas aeruginosa on long-term prognosis in COPD is unknown. The purpose of this study was to determine whether P. aeruginosa is associated with increased risk of exacerbations or death in patients with chronic obstructive pulmonary disease (COPD).

METHODS: This is a multiregional epidemiological study based on complete data on COPD outpatients between 1 January 2010 and 31 October 2017 and corresponding microbiology and national register data. Time-dependent Cox proportional hazards models and propensity matching was used to estimate hospitalisation-demanding exacerbations and death after two years, separately and in combination.

RESULTS: A total of 22.053 COPD outpatients were followed for a median of 1.082 days (interquartile-range: 427-1.862). P. aeruginosa was present in 905 (4.1%) patients. During 730 days of follow-up, P. aeruginosa strongly and independently predicted an increased risk of hospitalisation for exacerbation or all-cause death (HR 2.8, 95% CI 2.2-3.6; p<0.0001) and all-cause death (HR 2.7, 95% CI 2.3-3.4; p<0.0001) in analyses adjusted for known and suspected confounders. The signal remained unchanged in unadjusted analyses as well as propensity-matched subgroup analyses. Among patients "ever-colonized" with P. aeruginosa, the incidence of hospital-demanding exacerbations doubled after the time of the first colonization.

CONCLUSIONS: COPD patients with P. aeruginosa cultured from the airways had a markedly increased risk of exacerbations and death. It is still not clear whether this risk can be reduced by offering patients targeted antipseudomonal antibiotics. A randomised trial is currently recruiting patients to clarify this ( NCT03262142).

TidsskriftClinical Microbiology and Infection
StatusE-pub ahead of print - 22 jun. 2019

Bibliografisk note

Copyright © 2019. Published by Elsevier Ltd.

ID: 57456165